Conference Coverage

What’s new with adalimumab? Plenty


 

REPORTING FROM SDEF HAWAII DERMATOLOGY SEMINAR

Adalimumab citrate free

Not only does this new iteration of adalimumab do away with citrate as a buffer because it can cause pain and burning, it also utilizes a thinner 29-gauge needle rather than the standard 27-gauge. And the needle cover isn’t made with natural rubber latex. Also, both the pen and prefilled syringe contain half the volume of liquid, compared with the classic version of the biologic, so it’s 40 mg of drug in 0.4 mL rather than in 0.8 mL.

The packaging of adalimumab citrate free is different. It comes in a blue box to distinguish the product from the classic version.

Dr. Duffin reported receiving research grants from and serving as a consultant to AbbVie, which markets adalimumab, as well as close to a dozen other pharmaceutical companies.

The SDEF/Global Academy for Medical Education and this news organization are owned by the same parent company.

Pages

Recommended Reading

Chronic infections such as HCV, HIV, and TB cause unique problems for psoriasis patients
MDedge Dermatology
Brodalumab raced past ustekinumab to PASI 100
MDedge Dermatology
Comorbidities may cut effectiveness of psoriasis biologics
MDedge Dermatology
Guselkumab tops secukinumab over 48 weeks for plaque psoriasis
MDedge Dermatology
What’s New in Topical Treatments for Psoriasis
MDedge Dermatology
Psoriasis Treatment in Patients With Sickle Cell Disease
MDedge Dermatology
Safety and Efficacy of Halobetasol Propionate Lotion 0.01% in the Treatment of Moderate to Severe Plaque Psoriasis: A Pooled Analysis of 2 Phase 3 Studies
MDedge Dermatology
Clearance of Psoriasis After Ischemic Stroke
MDedge Dermatology
Different disease features found with family history of psoriasis versus PsA
MDedge Dermatology
Biologics curb coronary artery plaques in severe psoriasis
MDedge Dermatology